Serum albumin-bound proteomic signature for early detection and staging of hepatocarcinoma: sample variability and data classification.
BACKGROUND
Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) proteomic signature might be of interest for the early detection and staging of hepatocellular carcinoma (HCC). However, published procedures have been criticized for the lack of data about analytical reproducibility, and the use of inadequate data processing.


METHODS
MALDI-TOF profiling of peptides bound to serum albumin ("albuminome") was performed using 90 μL of serum from 45 study subjects (HCV-related cirrhosis, small, unifocal HCCs and advanced HCCs). To overcome the large intra-sample variability, a Quality Assurance protocol was implemented, and 4-8 samples for each subject were processed and analyzed. Overall, 522 subject samples and 299 quality-control spectra were analyzed. A machine-learning approach (Random Forest) was applied to analyze the data sets.


RESULTS
Mean intra-sample coefficient of variation (CV) of the analytical procedure was 17.6%-30.0%; inter-subject CV was in the range 48.8%-71.3% among the three study groups. The Random Forest procedure correctly classified 433/522 "patient samples" and 295/299 "reference samples"; 43/45 patients were correctly classified following this approach.


CONCLUSIONS
Our data suggest that, notwithstanding the large analytical variability found, multiple proteomic profiles obtained from each subject can differentiate cirrhosis with and without HCC, and HCCs with and without vascular invasion, warranting further investigation in a prospective setting.
Camaggi
Carlo M
CM
Dipartimento di Chimica Organica, Università di Bologna, Bologna, Italy.
Zavatto
Elena
E
Gramantieri
Laura
L
Camaggi
Valeria
V
Strocchi
Elena
E
Righini
Roberto
R
Merina
Luca
L
Chieco
Pasquale
P
Bolondi
Luigi
L
D000368:Aged; D000369:Aged, 80 and over; D001185:Artificial Intelligence; D014408:Biomarkers, Tumor / Q000097:blood / Q000737:chemistry / Q000378:metabolism; D001808:Blood Vessels / Q000473:pathology; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000150:complications / Q000175:diagnosis* / Q000473:pathology*; D003627:Data Interpretation, Statistical; D018450:Disease Progression; D055088:Early Detection of Cancer / Q000379:methods*; D005260:Female; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D008103:Liver Cirrhosis / Q000097:blood / Q000150:complications; D008113:Liver Neoplasms / Q000097:blood / Q000150:complications / Q000175:diagnosis* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D010455:Peptides / Q000097:blood / Q000737:chemistry / Q000378:metabolism; D011485:Protein Binding; D040901:Proteomics / Q000379:methods*; D015203:Reproducibility of Results; D012709:Serum Albumin / Q000378:metabolism*; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
D014408:Biomarkers, Tumor; D010455:Peptides; D012709:Serum Albumin